JP2017502006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502006A5 JP2017502006A5 JP2016539113A JP2016539113A JP2017502006A5 JP 2017502006 A5 JP2017502006 A5 JP 2017502006A5 JP 2016539113 A JP2016539113 A JP 2016539113A JP 2016539113 A JP2016539113 A JP 2016539113A JP 2017502006 A5 JP2017502006 A5 JP 2017502006A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 125000004452 carbocyclyl group Chemical group 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000547 substituted alkyl group Chemical group 0.000 claims 22
- 125000003107 substituted aryl group Chemical group 0.000 claims 22
- 239000013078 crystal Substances 0.000 claims 21
- 239000000651 prodrug Substances 0.000 claims 21
- 229940002612 prodrug Drugs 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 16
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000012526 B-cell neoplasm Diseases 0.000 claims 1
- 101100273739 Homo sapiens CD68 gene Proteins 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036934P | 2014-08-13 | 2014-08-13 | |
| US62/036,934 | 2014-08-13 | ||
| PCT/US2014/070162 WO2015089479A1 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502006A JP2017502006A (ja) | 2017-01-19 |
| JP2017502006A5 true JP2017502006A5 (enExample) | 2018-07-12 |
| JP6879740B2 JP6879740B2 (ja) | 2021-06-02 |
Family
ID=53371894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539113A Active JP6879740B2 (ja) | 2013-12-13 | 2014-12-12 | リンパ形質細胞性リンパ腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9856223B2 (enExample) |
| EP (1) | EP3079683A4 (enExample) |
| JP (1) | JP6879740B2 (enExample) |
| AU (1) | AU2014361798B2 (enExample) |
| CA (1) | CA2932351A1 (enExample) |
| WO (1) | WO2015089479A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| EP3313530B1 (en) * | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| EP3423451B1 (en) | 2016-03-01 | 2022-08-17 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
| JP2019507179A (ja) | 2016-03-01 | 2019-03-14 | プロペロン セラピューティックス インコーポレイテッド | Ｗｄｒ５タンパク質−タンパク質結合の阻害剤 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| WO2018049191A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TW201811799A (zh) * | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| WO2018140934A1 (en) | 2017-01-30 | 2018-08-02 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| EP3638671A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3638670B1 (en) | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| WO2018228920A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| US11427578B1 (en) | 2017-07-18 | 2022-08-30 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US11542251B2 (en) | 2018-02-14 | 2023-01-03 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物 |
| HRP20240541T1 (hr) | 2018-10-31 | 2024-07-05 | Gilead Sciences, Inc. | Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| EP3894406A1 (en) | 2018-12-11 | 2021-10-20 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| MXPA00010150A (es) | 1998-04-17 | 2002-05-14 | Parker Hughes Inst | Inhibidores de btk y metodos para su identificacion y uso. |
| RU2216541C2 (ru) | 1998-08-04 | 2003-11-20 | Астразенека Аб | Производные бензамида, способ их получения и фармацевтическая композиция на их основе |
| PT1115707E (pt) | 1998-09-25 | 2004-04-30 | Astrazeneca Ab | Derivados de benzamida e seu uso como inibidores de citocina |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| CA2385747A1 (en) | 1999-09-17 | 2001-03-22 | Gavin C. Hirst | Pyrazolopyrimidines as therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| ATE500837T1 (de) | 2002-12-05 | 2011-03-15 | Univ Arkansas | Molekulare determinanten des multiplen myeloms und deren verwendung |
| ES2571779T3 (es) | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| US20080064643A1 (en) | 2004-12-20 | 2008-03-13 | Paolo Carminati | Myd88 Homodimerization Inhibitors |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| UY29300A1 (es) | 2004-12-22 | 2006-07-31 | Astrazeneca Ab | Compuestos quimicos |
| RU2368602C2 (ru) | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| EP1912639A4 (en) | 2005-08-08 | 2011-10-12 | Janssen Pharmaceutica Nv | Thiazolopyrimidine KINASE INHIBITORS |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| GT200600411A (es) | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| EP1957461B1 (en) | 2005-11-14 | 2016-11-02 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| JP2009520784A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | キナゾリン誘導体、その製造方法および抗癌剤としてのその使用 |
| WO2007076474A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| EP2066351B1 (en) | 2006-10-02 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind cxcr4 and uses thereof |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EA200901377A1 (ru) | 2007-04-17 | 2010-06-30 | Новартис Аг | Соединения из ряда амидов нафталинкарбоновой и изохинолинкарбоновой кислот и их применение |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| EP2183232B1 (en) | 2007-08-02 | 2013-03-06 | Amgen, Inc | Pi3 kinase modulators and methods of use |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| US7982036B2 (en) * | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
| US8067423B2 (en) | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| US8338425B2 (en) | 2007-12-10 | 2012-12-25 | Concert Pharmaceuticals, Inc. | Heterocyclic kinase inhibitors |
| CA2723237A1 (en) | 2008-05-06 | 2009-11-12 | Peter A. Blomgren | Substituted amides, method of making, and use as btk inhibitors |
| TWI458721B (zh) | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| US7824861B2 (en) | 2008-07-10 | 2010-11-02 | National Tsing Hua University | Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site |
| LT3081552T (lt) | 2008-08-13 | 2021-06-10 | Mitsui Chemicals Agro, Inc. | Kenkėjų kontrolės agentas, turintis amido darinį ir kenkėjų kontrolės agento panaudojimas |
| MX2011001989A (es) | 2008-09-02 | 2011-03-30 | Boehringer Ingelheim Int | Nuevas benzamidas, su preparacion y su uso como medicamentos. |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| KR20160021308A (ko) | 2008-12-23 | 2016-02-24 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| RU2012109233A (ru) * | 2009-09-03 | 2013-10-10 | Аллерган, Инк. | Соединения как модуляторы тирозинкиназы |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| RU2560162C2 (ru) | 2010-02-08 | 2015-08-20 | Мерк Шарп и Доум Б.В. | СОЕДИНЕНИЯ 8-МЕТИЛ-1-ФЕНИЛИМИДАЗО[1, 5-а]ПИРАЗИНА |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| RU2604062C2 (ru) | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 |
| CA2815330A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| WO2012068096A2 (en) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| KR101581522B1 (ko) | 2011-05-23 | 2015-12-31 | 메르크 파텐트 게엠베하 | 피리딘 및 피라진 유도체 |
| KR20150144817A (ko) | 2011-06-10 | 2015-12-28 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| EP2726634B1 (en) | 2011-07-01 | 2017-02-22 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CN104011024B (zh) | 2011-10-03 | 2017-05-17 | 先正达参股股份有限公司 | 具有杀虫特性的2‑甲氧基苯甲酰胺衍生物 |
| CA2850763A1 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| BR112014010439A2 (pt) | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| ES2705001T3 (es) | 2011-11-09 | 2019-03-21 | Bristol Myers Squibb Co | Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4 |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| EP2790705B1 (en) | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
| EP2878601B1 (en) | 2012-07-27 | 2018-03-28 | Riken | Agent for treating or controlling recurrence of acute myelogenous leukemia |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| EP3044338B1 (en) | 2013-09-12 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US10612095B2 (en) | 2013-12-06 | 2020-04-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| US10112957B2 (en) | 2014-10-22 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| RU2726367C2 (ru) | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| EP3448390A1 (en) | 2016-04-29 | 2019-03-06 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| CN106008371A (zh) | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN106279120A (zh) | 2016-07-15 | 2017-01-04 | 谢阳 | 一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用 |
| CN107056786B (zh) | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
| JP2021506735A (ja) | 2017-05-26 | 2021-02-22 | イクノス サイエンシズ エスエー | 新規ｍａｐ４ｋ１阻害剤 |
| EP4041401A1 (en) | 2019-10-08 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| WO2021071922A1 (en) | 2019-10-08 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases |
-
2014
- 2014-12-12 JP JP2016539113A patent/JP6879740B2/ja active Active
- 2014-12-12 EP EP14869964.8A patent/EP3079683A4/en not_active Withdrawn
- 2014-12-12 CA CA2932351A patent/CA2932351A1/en not_active Abandoned
- 2014-12-12 WO PCT/US2014/070162 patent/WO2015089479A1/en not_active Ceased
- 2014-12-12 AU AU2014361798A patent/AU2014361798B2/en not_active Ceased
- 2014-12-12 US US15/104,132 patent/US9856223B2/en not_active Ceased
- 2014-12-12 US US17/534,896 patent/USRE50030E1/en active Active
-
2017
- 2017-12-19 US US15/847,430 patent/US10633348B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502006A5 (enExample) | ||
| JP2017504595A5 (enExample) | ||
| JP2018515434A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2019527682A5 (enExample) | ||
| JP2018522867A5 (enExample) | ||
| JP2020509022A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2019514874A5 (enExample) | ||
| JP2010528089A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2014510774A5 (enExample) | ||
| JP2018509438A5 (enExample) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2010280669A5 (enExample) | ||
| JP2011518811A5 (enExample) | ||
| HRP20211352T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| JP2016507502A5 (enExample) |